Skip to Content


Team Members:
  • Pascal Acree
  • Amee Kapadia
  • Darsh Patel
  • Ronak Mahatme
  • Lucia Zhang
  • Charlie Almoney
  • Morgan Kofsky
  • Brian Park
  • Mehran Habibi, MD
  • Sara Alcorn, MD
  • Kristin Broderick, MD
  • Shababa Matin


Of the 250,000 women diagnosed with breast cancer annually in the US, 60% are treated with breast conserving surgery (BCS): a lumpectomy followed by targeted radiotherapy. Around 22,500 BCS patients further undergo oncoplastic reconstruction of the breast following lumpectomy to improve cosmetic outcomes. After the procedure, the surgical margins (edges) of the specimen are sent to pathology, guiding radiation planning. However, during oncoplastic reconstruction, the margins and tissue around the tumor bed are moved, making it nearly impossible for radiation oncologists to precisely delineate the cavity when planning follow-upradiotherapy targeted to the breast. Imprecise delineation of the tumor bed compromises radiotherapy efficacy as it leads to the radiation oncologist either having to increase dosage to the cavity or increase number of therapy sessions required, exacerbating the side effects and costs of treatment. However, if the irradiation dosage or quantity of dose fractions administered is not increased, rates of cancer recurrence increase. EdgeSense has developed a novel fiducial marker that provides accuracy and reliability for post-operative breast cancer radiation therapy, bringing confidence to radiation oncologists and comfort to patients.

Watch Video

Read the Johns Hopkins University privacy statement here.